INTRODUCTION {#sec0005}
============

Sex differences have been established in prevalence and rates of decline in Alzheimer's disease (AD) \[[@ref001]\], and a growing body of literature shows that sex differences also exist in early resilience to the neural burden of AD. Specifically, researchers have shown that women's established verbal memory advantage over men \[[@ref009]\] functions as a form of sex-specific cognitive reserve, affording women equal or better memory performances when compared to men despite positive neuroimaging biomarkers for AD, including mild to moderate levels of hippocampal atrophy \[[@ref009]\], hypometabolism on fluorodeoxyglucose (FDG) positive emission tomography (PET) \[[@ref010]\], and brain amyloid burden as measured by a positive florbetapir PET (A+) \[[@ref011]\].

Beyond cognitive reserve, recent research by our group suggests women may have neural reserve in the face of early AD pathology as indicated by biomarkers. Specifically, we have demonstrated that women--- and not men--- with A+ and normal cognition (NC) show right hippocampal volumes comparable to women with NC and a negative florbetapir PET study (A--); however, this sex-specific advantage is lost in early mild cognitive impairment (eMCI) \[[@ref012]\]. Mechanisms of this proposed sex-based hippocampal reserve remain unclear, but may include a complex host of interactive factors including lifetime neuroprotective effects of estrogen \[[@ref013]\], and sex differences in genetic \[[@ref005]\], inflammatory \[[@ref016]\], metabolic \[[@ref017]\], and psychosocial factors \[[@ref018]\].

Given the known route of progression of AD pathology through the hippocampus \[[@ref019]\], researchers have emphasized the potential importance of examining hippocampal subfield volumes (SV). In particular, Cornu Ammonis 1 (CA1) and subiculum show pathology related to AD first, and changes in these regions also predict conversion to symptomatic AD \[[@ref020]\]. In addition, subiculum changes have been correlated with cortical amyloid burden \[[@ref026]\], and CA1 changes have been linked to memory encoding and retrieval deficits \[[@ref020]\]. Recent comprehensive reviews show CA1 as most consistently implicated in AD, and CA1 and subiculum in eMCI and individuals at risk for AD; however, findings are not fully consistent across methodologies, and other regions, including CA2, 3, 4, and dentate gyrus, have also been implicated in early disease \[[@ref029]\].

The current study extends our previous work with whole hippocampal volumes \[[@ref012]\]. In addition to replicating prior whole hippocampus findings with advanced segmentation technology and methods for controlling confounding factors \[[@ref030]\], we examined whether sex and diagnosis moderate the effects of A+ on hippocampal SV. Specifically, we hypothesized that NC women with A+ would show CA1 and subiculum volumes comparable to NC women with A−. Although the literature has shown more tenuous support for AD-related changes in CA3, CA4, and dentate gyrus, such findings are nonetheless present, and as such we hypothesized that NC women with A+ would also show volumes in these regions comparable to NC women with A−. We hypothesized that this sex-based hippocampal subfield advantage would be lost in eMCI, with A+ effects being detrimental across sexes.

MATERIALS AND METHODS {#sec0010}
=====================

Participants {#sec0015}
------------

ADNI is a longitudinal, multi-site AD biomarkers study. This study was conducted in accordance with guidelines on human experimentation and ethical standards of the Committee on Human Experimentation and approved by local Institutional Review Boards at each participating ADNI site. Participants from ADNI2 (NC *n* = 178; MCI *n* = 232) and ADNIGO (MCI *n* = 110) were selected as described previously \[[@ref011]\]. The Alzheimer's Disease Neuroimaging Initiative (ADNI) required NC participants to have Mini-Mental State Examination (MMSE) \[[@ref033]\] scores of 24--30, Clinical Dementia Rating (CDR) \[[@ref034]\] of 0, and no memory complaints. ADNI defined early eMCI as including MMSE score of 24--30, CDR of 0.5, CDR memory box score of 0.5 or greater, objective memory loss as assessed by education-adjusted scores on the Wechsler Memory Scale Logical Memory II test (Raw scores = 9--11 for \>16 years education; 8--15 for 5--9 years education; 0--7 for 3--6 years education), subjective memory complaint, and not meeting criteria for dementia \[[@ref035]\]. ADNI data methodology and associated neuroimaging quality control procedures can be found at <http://www.adni-info.org>.

Hippocampal image processing {#sec0020}
----------------------------

MRI scans were obtained at baseline according to standardized protocol (<http://adni.loni.usc.edu/methods/mri-analysis/mri-acquisition/>). T1-weighted images (Multiplanar Reconstruction (MPR) or Inversion Recovery-Spoiled Grass (IR-SPGR)) were downloaded from ADNI in Neuroimaging Informatics Technology Initiative (NiFTI) format and were selected among scans within six months of screening. Images were inspected manually for quality assurance, and also met Mayo Clinic quality control documentation guidelines (as described at <http://adni.loni.usc.edu/>). Hippocampal volume and subfield segmentation and determination of total intracranial volume (TIV) was performed in-house using Freesurfer 6.0 (documented and freely available for download online: <http://surfer.nmr.mgh.harvard.edu/>) \[[@ref030]\]. Freesurfer was employed for automated Talairach transformation, removal of non-brain tissue using a hybrid watershed/surface deformation procedure \[[@ref037]\], intensity normalization \[[@ref040]\], segmentation of the subcortical white matter and deep gray matter volumetric structures (including hippocampus and subfields) \[[@ref030]\], tessellation of the gray matter white matter boundary, automated topology correction \[[@ref042]\], and surface deformation following intensity gradients to optimally place the gray/white and gray/cerebrospinal fluid borders \[[@ref044]\]. Note that subfields of interest available from Freesurfer 6.0 included CA1, subiculum, CA3, CA4, and granule cell/molecular layer/dentate gyrus (latter referred to as dentate gyrus in manuscript).

Present analyses examined left and right total hippocampal volumes (HV) and right subfield volumes (SV), based on significant hemisphere by sex by amyloid status interactions found previously \[[@ref012]\]. We adjusted HV and SV for TIV as described previously \[[@ref012]\].

Florbetapir PET image processing {#sec0025}
--------------------------------

We downloaded fully processed baseline visit, 18-F PET binary positivity/negativity images (4×5 minute frames; 50--70 minutes post-injection) from ADNI \[[@ref047]\]. As described by other research groups, prior to download, images were realigned, averaged, resliced to 1.5 mm^3^ voxel size, smoothed to 8 mm full width at half maximum, and co-registered to baseline native-space structural MRI scans, which were segmented and parcellated with Freesurfer (Version 5.3.0) to define cortical grey matter regions of interest (frontal, anterior/posterior cingulate, lateral parietal, lateral temporal) \[[@ref031]\]. Amyloid positivity was determined by extracting weighted cortical retention means (regional standardized uptake value or SUVRs) from these regions, calculating average SUVR, and dividing by the cerebellum SUVR as a reference (1.11 SUVR ratio threshold) \[[@ref048]\].

APOE carrier status {#sec0030}
-------------------

We downloaded fully processed APOE genotype data from ADNI. A binary variable was created, coding individuals as APOE4 carriers (heterozygotes, *n* = 169; homozygotes, *n* = 37) or non-carriers.

Clinical measures {#sec0035}
-----------------

We included modified total score on the Montreal Cognitive Assessment (MoCA) \[[@ref050]\] as a measure of baseline cognition. In order to create a measure unbiased by memory deficits, points earned for delayed list word recall were excluded, resulting in a maximum score of 25.

Statistical methods {#sec0040}
-------------------

All analyses were performed using Statistical Package for the Social Sciences (SPSS) and the Process Macro \[[@ref051]\]. Six participants either failed the Mayo Clinic quality control standards or were not successfully segmented with Freesurfer 6.0, and were excluded, resulting in 520 total participants.

Mann-Whitney U tests examined group differences in demographic control variables. Two moderation regression analyses examined whether sex and diagnosis moderated effects of amyloid status on left and right HV, respectively, in order to replicate prior findings with the latest version of Freesurfer. Based on prior findings showing effects on the right, but not left hippocampus \[[@ref012]\], five additional regressions examined moderating effects of sex and diagnosis on amyloid impact on right CA1, CA3, CA4, subiculum, and dentate gyrus. For all analyses, A+ was treated as an independent variable, diagnosis as a moderator, and sex as a secondary moderator. Modified MoCA scores, age at screening, education, and APOE4 carrier status were included as covariates. Continuous covariates were mean-centered; dichotomous covariates were zero-centered.

Statistical model equation for each outcome Y is presented as: $$\begin{array}{rcl}
Y & & {= \beta_{0} + \beta_{1}X + \beta_{2}M + \beta_{3}W + \beta_{4}\mathit{XM}} \\
 & & {\mspace{9mu}\mspace{9mu} + \beta_{5}\mathit{XW} + \beta_{6}\mathit{MW} + \beta_{7}\mathit{XMW} + \beta_{8}\mathit{Age}} \\
 & & {\mspace{9mu}\mspace{9mu} + \beta_{9}\mathit{Education} + \beta_{10}\mathit{MoCA} + \beta_{11}\mathit{APoE},} \\
\end{array}$$ where Y represents the hippocampal or subfield volume, X is the amyloid status, M is the diagnostic result (Normal or MCI), and W is sex (F or M). We ran this moderation model for each volume considered in this research, with a total of 7 times.

For each of the moderation analyses, outlying and influential data points were defined as those that failed two of three thresholds: 1) Cook's D, *D* \> 4 / (*n* -- *k* -- 1), where *n* = number of participants in the analysis, and *k* = number of predictors; 2) leverage as defined by (2*k*+2)/*n*, where *n* = number of participants in the analysis, and *k* = number of predictors; and 3) Maholonobis value greater than Chi-square cutoff at *p* \< 0.001 (degrees of freedom = 6).

RESULTS {#sec0045}
=======

Demographics {#sec0050}
------------

Of 520 participants, 48.3% were women, 232 had A+, 204 were APOE4 carriers, and 342 were diagnosed with eMCI. The average age was 71.3 years (SD = 6.9) and ranged from 55--89 years. Additional demographics and brain volume information by diagnosis, sex, and amyloid status are available in [Table 1](#jad-64-jad180028-t001){ref-type="table"}.

###### 

Sample characteristics by diagnosis, sex, and amyloid status

                                  Normal Controls (NC)                                                               
  --------------------- ---------------------------------------- ------------------------- ------------------------- -------------------------
  Demographics                                                                                                       
   Number                                  59                               34                        69                        16
   Age (y)                             70.9 (4.9)                       72.9 (5.1)                73.4 (6.5)                76.8 (5.4)
   Education (y)                       16.1 (2.5)                       15.2 (2.5)                17.2 (2.2)                17.4 (2.4)
  Caucasian (%)                           93.2                             94.1                      91.3                       100
   Hispanic (%)                           8.5                               2.9                       4.3                        0
  Cognition                                                                                                          
   Modified MoCA                       23.5 (1.5)                       23.5 (1.5)                23.3 (1.7)                23.1 (1.4)
  APOE Carrier Status                                                                                                
   E4 Carriers                             17                               17                         8                         9
  Brain Volumes^a^                                                                                                   
   L HV                              3020.8 (313.9)                   2979.6 (326.1)            3291.0 (380.8)            3104.5 (236.2)
   R HV                              3139.1 (350.7)                   3108.4 (364.8)            3427.5 (364.0)            3138.7 (300.7)
   L Subiculum                        384.2 (42.3)                     381.6 (49.1)              423.9 (54.9)              389.4 (40.9)
   R Subiculum                        390.0 (46.3)                     388.0 (48.8)              425.9 (50.7)              377.8 (39.4)
   L CA1                              559.9 (70.3)                     551.0 (70.0)              616.3 (79.7)              587.1 (57.3)
   R CA1                              588.5 (71.1)                     593.7 (87.4)              649.8 (81.3)              603.6 (77.9)
   L GC/ML/DG                         259.4 (31.2)                     253.0 (30.9)              278.1 (36.1)              262.3 (22.6)
   R GC/ML/DG                         272.3 (36.9)                     265.7 (35.6)              295.5 (37.1)              272.1 (30.4)
   L CA3                              182.0 (26.9)                     180.5 (28.1)              195.5 (28.6)              191.8 (20.6)
   R CA3                              201.7 (31.9)                     197.3 (32.2)              220.3 (30.9)              210.3 (28.5)
   L CA4                              224.8 (26.3)                     221.1 (24.7)              240.4 (30.7)              229.3 (18.1)
   R CA4                              235.9 (31.1)                     231.5 (29.8)              255.7 (31.3)              236.9 (25.0)
   TIV                          1.38×10^6^ (1.10×10^5^)           1.40×10^6^ (1.34×10^5^)   1.57×10^6^ (1.36×10^5^)   1.60×10^6^ (1.37×10^5^)
                         Early Mild Cognitive Impairment (eMCI)                                                      
                                      Women (158)                        Men (184)                                   
                                       Amyloid −                         Amyloid +                 Amyloid −                 Amyloid +
  Demographics                                                                                                       
   Number                                  75                               83                        85                        99
   Age (y)                             69.0 (8.1)                       70.6 (7.6)                68.9 (7.3)                73.1 (5.6)
   Education (y)                       15.8 (2.4)                       15.8 (2.9)                16.7 (2.6)                16.3 (2.8)
   Caucasian (%)                           88                              92.8                      90.6                       99
   Hispanic (%)                           6.7                               3.6                       4.7                        2
  Cognition                                                                                                          
   Modified MoCA                       22.6 (2.1)                       22.0 (2.3)                22.5 (2.1)                21.9 (2.5)
  APOE Carrier Status                                                                                                
   E4 Carriers                             17                               53                        21                        62
  Brain Volumes^a^                                                                                                   
   L HV                              2984.1 (387.1)                   2777.6 (376.5)            3202.5 (447.8)            2973.6 (430.5)
   R HV                              3089.2 (412.5)                   2843.1 (416.4)            3338.8 (465.1)            3129.1 (411.3)
   L Subiculum                        381.9 (58.5)                     355.1 (55.3)              407.2 (64.4)              375.4 (63.2)
   R Subiculum                        383.5 (64.6)                     351.8 (59.5)              408.5 (64.1)              378.9 (59.8)
   L CA1                              548.5 (68.7)                     513.1 (70.5)              599.7 (88.2)              571.1 (80.3)
   R CA1                              579.5 (77.5)                     533.0 (78.3)              637.2 (96.0)              603.6 (79.3)
   L GC/ML/DG                         254.7 (34.0)                     236.8 (36.0)              272.1 (40.8)              254.1 (39.5)
   R GC/ML/DG                         270.7 (38.7)                     247.3 (39.5)              291.5 (42.8)              277.1 (36.9)
   L CA3                              176.3 (25.3)                     167.6 (26.5)              194.1 (29.8)              184.2 (33.1)
   R CA3                              199.3 (33.5)                     183.5 (32.4)              217.5 (36.8)              211.2 (32.3)
   L CA4                              220.9 (27.5)                     207.0 (30.1)              237.5 (33.3)              222.3 (32.7)
   R CA4                              234.2 (32.0)                     215.7 (33.3)              252.7 (35.4)              242.8 (31.2)
   TIV                          1.41×10^6^ (1.52×10^5^)           1.39×10^6^ (1.37×10^5^)   1.60×10^6^ (1.36×10^5^)   1.62×10^6^ (1.52×10^5^)

Note: Mean (SD) shown for continuous variables. ^a^Raw, uncorrected volume values in mm^3^. MoCA, Montreal Cognitive Assessment; APOE, apolipoprotein E; HV, hippocampal volume; L, left; R, right; CA, cornu ammonis; GC, granule cell layer; ML, molecular layer; DG, dentate gyrus; TIV, total intracranial volume.

Mann-Whitney tests showed that for NC, men were significantly older, *p* = 0.01, more educated, *p* \< 0.001, and more often APOE4 carriers *p* = 0.02 than women. For eMCI, men were also significantly older, *p* = 0.04 and more educated, *p* = 0.02 than women. There were no sex differences in modified MoCA score for NC or eMCI.

Mann-Whitney tests showed that for NC, individuals with A+ were significantly older, *p* = 0.04, less educated, *p* = 0.05, and more frequently APOE4 carriers, *p* \< 0.001 than A−. No differences based on A+ were observed in modified MoCA scores for NC. For eMCI, individuals with A+ were significantly older, *p* \< 0.001, had lower modified MoCA scores, *p* = 0.02, and were more often APOE4 carriers, *p* \< 0.001 than A−. No differences based on A+ were observed in education for eMCI.

Sex moderation of diagnosis and amyloid status effects on hippocampal total and subfield volume {#sec0055}
-----------------------------------------------------------------------------------------------

### Total hippocampal volume {#sec0060}

In a replication of prior work with new techniques, the model with A+, diagnosis, sex, and their interactions predicting left HV was significant, F(11, 505) = 17.80; *p* \< 0.001; R^2^ = 0.29, yet the three-way interaction of A+, diagnosis, and sex was not significant, t(505) = −1.09, *p* = 0.27, indicating no moderating effects of sex and diagnosis on A+ effects for the left HV. Also replicating prior results, the model with A+, diagnosis, sex, and their interactions predicting right HV was significant, F(11, 505) = 18.10; *p* \< 0.001; R^2^ = 0.28, and the three-way interaction of A+, diagnosis, and sex was also significant, showing sex moderated the effects of diagnosis and A+ on right HV, t(505) = −2.02, *p* = 0.04. Parsing this interactive effect indicated that there were differences in the interactive effects of sex and amyloid status on right hippocampus volume in NC t(505) = 1.95, *p* = 0.05, but not eMCI t(505) = −0.77, *p* = 0.44. Specifically, there was no relationship of A+ to HV in NC women t(505) = −0.15, *p* = 0.88, but A+ related to smaller right HV in NC men t(505) = −2.44, *p* = 0.02. At the eMCI stage, A+ appeared to have a detrimental effect on right HV regardless of sex (men: t(505) = −1.64, *p* = 0.10; women t(505) = −2.78, *p* = 0.01). See [Table 2](#jad-64-jad180028-t002){ref-type="table"} and [Figs. 1A](#jad-64-jad180028-g001){ref-type="fig"} and [2A](#jad-64-jad180028-g002){ref-type="fig"}.

###### 

Summary of regression moderation analyses for left and right hippocampus and right subfield volume outcomes (N = 520)

  Variable                       Left Hippocampus                                        
  ----------------------------- ------------------- ---------- ------------------------- ---------
  Amyloid PET Positivity (A+)        −105.474         0.002            −171.956           −38.992
  Diagnosis                          −128.397         0.0001           −190.539           −66.256
  Sex                                 −62.661         0.043            −123.325           −1.997
  A+×Diagnosis×Sex                   −131.935         0.275            −369.027           105.157
  A+×Diagnosis                        −53.209         0.377            −171.326           64.907
  A+×Sex                              54.453          0.358             −61.896           170.802
  Diagnosis×Sex                       −47.715          0.43            −166.427           70.998
  Age                                 −22.373        \<0.0001           −27.119           −17.626
  Education                            2.159          0.717             −9.514            13.833
  Modified MoCA                        32.95         \<0.0001           18.655            47.244
  APOE4 Carrier Status                −5.234          0.883             −74.798            64.33
  Variable                       Right Hippocampus                                       
                                        *B*            *p*      95% Confidence Interval  
  Amyloid PET Positivity (A+)        −125.602         0.001            −200.745           −50.46
  Diagnosis                          −119.442         0.001            −191.152           −47.732
  Sex                                 −70.393         0.049            −140.513           −0.272
  A+×Diagnosis×Sex                    −279.86         0.044            −552.656           −7.065
  A+×Diagnosis                        −14.367         0.837            −151.412           122.678
  A+×Sex                              76.974          0.266             −58.725           212.674
  Diagnosis×Sex                      −115.019         0.101            −252.623           22.586
  Age                                 −22.702        \<0.0001           −27.659           −17.746
  Education                           −6.647          0.288             −18.926            5.633
  Modified MoCA                       31.886          0.0001            15.846            47.927
  APOE4 Carrier Status                −33.041         0.375            −106.172           40.089
  Variable                        Right Subiculum                                        
                                        *B*            *p*      95% Confidence Interval  
  Amyloid PET Positivity (A+)         −16.199         0.003             −26.948            −5.45
  Diagnosis                           −17.937         0.0006            −28.162           −7.713
  Sex                                 −9.603          0.054             −19.379            0.173
  A+×Diagnosis×Sex                    −42.895         0.033             −82.367           −3.423
  A+×Diagnosis                         −1.78           0.86             −21.549           17.989
  A+×Sex                              16.042          0.105             −3.388            35.471
  Diagnosis×Sex                       −11.939         0.238             −31.799            7.921
  Age                                 −2.853         \<0.0001           −3.579            −2.128
  Education                           −0.963          0.314             −2.839             0.913
  Modified MoCA                        3.972          0.0009             1.638             6.306
  APOE4 Carrier Status                −9.156          0.093             −19.85             1.538
  Variable                           Right CA1                                           
                                        *B*            *p*      95% Confidence Interval  
  Amyloid PET Positivity (A+)         −18.657         0.025             −34.958           −2.356
  Diagnosis                           −22.802         0.005             −38.743            −6.86
  Sex                                 −21.379         0.007             −36.94            −5.818
  A+×Diagnosis×Sex                    −55.788         0.067             −115.54            3.967
  A+×Diagnosis                        −15.027         0.329             −45.257           15.202
  A+×Sex                              14.284          0.348             −15.597           44.166
  Diagnosis×Sex                       −33.353          0.03             −63.448           −3.258
  Age                                 −3.265         \<0.0001           −4.279            −2.251
  Education                           −0.948           0.48             −3.584             1.688
  Modified MoCA                        5.098          0.003              1.769             8.426
  APOE4 Carrier Status                 −6.82          0.384             −22.198            8.559
  Variable                        Right GC/ML/DG                                         
                                        *B*            *p*      95% Confidence Interval  
  Amyloid PET Positivity (A+)         −11.867         0.001             −19.087           −4.648
  Diagnosis                            −5.17          0.142             −12.07             1.731
  Sex                                 −9.548          0.006             −16.275           −2.821
  A+×Diagnosis×Sex                    −22.562         0.089             −48.611            3.49
  A+×Diagnosis                        −1.127          0.865             −14.168           11.914
  A+×Sex                               1.188          0.858             −11.836           14.212
  Diagnosis×Sex                       −10.969         0.101             −24.072            2.134
  Age                                 −1.671         \<0.0001           −2.139            −1.203
  Education                           −0.679          0.259             −1.859             0.502
  Modified MoCA                        3.699         \<0.0001            2.086             5.311
  APOE4 Carrier Status                 0.04           0.991             −6.979             7.06
  Variable                           Right CA3                                           
                                        *B*            *p*      95% Confidence Interval  
  Amyloid PET Positivity (A+)          −8.18          0.015             −14.75             −1.61
  Diagnosis                           −3.026          0.326             −9.075             3.023
  Sex                                  −7.11          0.018             −13.014           −1.206
  A+×Diagnosis×Sex                    −13.056         0.265             −36.04             9.928
  A+×Diagnosis                        −2.195          0.706             −13.603            9.213
  A+×Sex                               −2.07          0.722             −13.51             9.369
  Diagnosis×Sex                       −9.438          0.108             −20.95             2.075
  Age                                 −0.707          0.0006             −1.11            −0.303
  Education                            −0.07          0.898             −1.141             1.001
  Modified MoCA                        2.842          0.0001             1.461             4.223
  APOE4 Carrier Status                 3.786          0.246             −2.619            10.191
  Variable                           Right CA4                                           
                                        *B*            *p*      95% Confidence Interval  
  Amyloid PET Positivity (A+)         −9.573          0.003             −15.783           −3.364
  Diagnosis                           −3.596          0.225             −9.412             2.22
  Sex                                 −7.726          0.008             −13.46            −1.992
  A+×Diagnosis×Sex                    −20.095         0.075             −42.246            2.057
  A+×Diagnosis                        −0.594          0.916             −11.615           10.428
  A+×Sex                               1.228          0.827             −9.834             12.29
  Diagnosis×Sex                       −10.412         0.067             −21.534            0.71
  Age                                 −1.189         \<0.0001           −1.588            −0.789
  Education                            −0.55           0.28             −1.549             0.449
  Modified MoCA                        2.918         \<0.0001            1.548             4.289
  APOE4 Carrier Status                 0.845          0.782             −5.149             6.839

Note: Age, education, and modified MoCA scores were centered at their means. Dichotomous variables were centered around zero. PET, positron emission tomography; A+, positive amyloid PET scan; MoCA, Montreal Cognitive Assessment; APOE, apolipoprotein E; CA, cornu ammonis; GC, granule cell layer; ML, molecular layer; DG, dentate gyrus. Left Hippocampus model *R* = 0.539, *p* \< 0.0001. Right Hippocampus model *R* = 0.525, *p* \< 0.0001. Right subiculum model *R* = 0.481, *p* \< 0.0001. Right CA1 model *R* = 0.440, *p* \< 0.0001. Right GC/ML/DG model *R* = 0.472, *p* \< 0.0001. Right CA3 model *R* = 0.347, *p* \< 0.0001. Right CA4 model *R* = 0.433, *p* \< 0.0001.

![Sex moderation of diagnosis and amyloid status effects. Sex moderates effects of diagnosis and Florbetapir PET amyloid positivity (A+) on right whole hippocampal volume (A), and right subiculum (B). Specifically, normal control (NC) women with A+ show whole and subfield volumes more comparable to NC women with a negative amyloid PET (A−), while NC men do not. At the early mild cognitive impairment (eMCI) stage, effects of A+ on total and subfield volume did not differ by sex, but generally related to smaller volumes across participants. A--, ^18^F-PET amyloid negative; A+, ^18^F-PET amyloid positive. For ease of viewing, hippocampus and subfield volume units are raw, uncorrected, in milimeters^3^.](jad-64-jad180028-g001){#jad-64-jad180028-g001}

![Alternate presentation of sex moderation of diagnosis and amyloid status effects (breakdown by amyloid status). Sex moderates effects of diagnosis and Florbetapir PET amyloid positivity (A+) on right whole hippocampal volume (A), and right subiculum (B). Specifically, normal control (NC) women with A+ show whole and subfield volumes more comparable to NC women with a negative amyloid PET (A−), while NC men do not. At the early mild cognitive impairment (eMCI) stage, effects of A+ on total and subfield volume did not differ by sex, but generally related to smaller volumes across participants. Although not directly tested in this analysis, as shown, this figure also suggests that for A+ individuals, receiving an eMCI diagnosis is related to smaller volumes, specifically in women. A--, ^18^F-PET amyloid negative; A+, ^18^F-PET amyloid positive. For ease of viewing, hippocampus and subfield volume units are raw, uncorrected, in milimeters^3^.](jad-64-jad180028-g002){#jad-64-jad180028-g002}

### Subfield volume {#sec0065}

Following the significant right HV analysis, right hippocampal SV analyses showed the model for right subiculum was significant, F(11, 505) = 13.44; *p* \< 0.001; R^2^ = 0.23, and the sex by diagnosis by amyloid status interaction was also significant, t(505) = −2.14, *p* = 0.03. Parsing the interaction showed sex differences in the effect of A+ on subiculum volume in NC participants t(505) = 2.38, *p* = 0.02. Specifically, there was no relationship of A+ to subiculum volume in NC women t(505) = 0.35, *p* = 0.73, but A+ related to smaller subiculum volumes in NC men t(505) = −2.67, *p* = 0.01. Similar to findings for the whole right hippocampus, the interaction of sex and amyloid status was not significant in eMCI t(505) = −0.44, *p* = 0.66, but rather suggested that A+ is linked to smaller subiculum volumes in eMCI regardless of sex (men: t(505) = −1.64, *p* = 0.10; women: t(505) = −2.17, *p* = 0.03). See [Table 2](#jad-64-jad180028-t002){ref-type="table"} and [Figs. 1B](#jad-64-jad180028-g001){ref-type="fig"} and [2B](#jad-64-jad180028-g002){ref-type="fig"}.

While regression models were significant for the remaining SV (*p* \< 0.001), sex by diagnosis by amyloid status interaction effects for these subfields were either at trend-level (right CA1, t(505) = −1.83, *p* = 0.07; right CA4, t(505) = −1.78, *p* = 0.08; right dentate gyrus, t(505) = −1.70, *p* = 0.09) or not significant (right CA3, t(505) = −1.12, *p* = 0.27). Within subfields showing trend-level three-way interactions, the pattern of findings was similar to the effect pattern for the subiculum (i.e., trends toward greater impact of A+ on SV in NC men than NC women, and general detrimental effects of A+ in eMCI across sexes). See [Table 2](#jad-64-jad180028-t002){ref-type="table"}.

DISCUSSION {#sec0070}
==========

The current study examined whether sex and diagnosis moderate impact of amyloid positivity on hippocampal subfield volume. We hypothesized NC women with A+ would show hippocampal subfield volumes comparable to those in NC women with A-- in right CA1, subiculum, CA3, CA4, and dentate gyrus, implying resistance to early impact of disease, but that A+ status would be associated with smaller right SV across sexes in eMCI. This prediction was partially supported; sex and diagnosis significantly moderated amyloid and diagnosis effects on right subiculum, and trends were observed for right CA1, CA4, and dentate gyrus. Specifically, NC men with A+ showed significantly smaller subiculum volume than their A-- counterparts, while this effect was not seen in NC women. At the eMCI stage, A+ was associated with smaller subiculum volume regardless of sex. Trend level results for the CA1, CA4, and dentate gyrus followed a similar pattern (i.e., NC men with A+ showed SV that were smaller than NC men with A--, but this effect was not observed in NC women; individuals with eMCI and A+ showed smaller SV than individuals with eMCI and A--, regardless of sex). Effects were observed while accounting for effects of baseline cognitive status, age, education, APOE4 carrier status, and total brain volume.

The present findings suggest women have neural reserve at the level of the subiculum, a hippocampal subfield impacted very early in the progression of AD pathology. Specifically, we demonstrated that subiculum volume in women appears to resist effects of, or be maintained despite presence of, A+ at the NC stage. In other words, women with NC, but high likelihood of developing AD (i.e., A+), have subiculum volumes that are consistent with those of healthy women. On the other hand, men with NC and increased likelihood for AD (i.e., A+) show smaller subiculum volumes than healthy men, even before impairments are noted on formal memory measures. Combined with recent research supporting memory reserve for women with fewer prodromal AD traits \[[@ref009]\], the present results suggest that examining memory and hippocampal volume may more sensitively identify men than women at risk for future decline, though recent research additionally suggests that looking at changes in hippocampal volume over time may assist with prediction of AD in women \[[@ref053]\]. This has important implications for both clinical decision making and selection and outcome measures in clinical trials.

The mechanism for sex effects on rates of hippocampal atrophy remains unclear and is an area for future study. One avenue to consider is that while estrogen loss at menopause and certain hormone therapy approaches have been examined as a risk factor for cognitive decline (for a review, see \[[@ref054]\]), it has been more difficult to consider the earlier protective effects of estrogen and how those may play out, or interact with sexually dimorphic inflammatory \[[@ref016]\] and metabolic factors \[[@ref017]\]. In addition, much recent research has suggested the importance of both creating higher-level risk categories combining across biomarkers and controlling for comorbid risks, such as APOE4 carrier status, \[[@ref015]\] age \[[@ref055]\], education, and lifestyle factors (e.g., exercise, smoking, and alcohol use). As many of these factors differ by sex, the present results emphasize that sex should be considered in these types of analyses. Recent research also suggests that examining the hippocampus from an anterior-to-posterior perspective combined with anatomical labeling may yield additional information \[[@ref057]\].

Strengths of the present study include a relatively large, well-characterized study sample, use of the latest hippocampal segmentation technology \[[@ref030]\], and rigorous control of potential confound variables according to recent field recommendations \[[@ref015]\]. At the same time, all methods of segmentation are vulnerable to errors, particularly with single anatomical images without very high resolution (i.e., greater than 3T as employed here). Future studies should replicate these findings with multiple images and at higher field strength, and with complementary methods for examining hippocampal structure, such as shape and radial distance analyses. In addition, the ADNI sample includes highly educated individuals with a restricted range of education; replication in other, more representative samples will be important. It also will be essential to examine sex differences in AD biomarkers longitudinally, to facilitate understanding of when exactly--- or how much--- pathology leads to cognitive, atrophic, and clinical symptom expression. Moreover, while the current investigation found significant three-way interactions representing an important preliminary finding, replication in larger samples will be necessary to ascertain that effects observed here are stable, truly sex-specific, and lateralized outside of the present sample, as well as to explore whether other subfields might reach significance. Additional investigation of the effects of estrogen levels and hormone replacement therapy will also be important in the future.

In sum, the present study provides additional evidence that in the face of AD, women have early neural reserve at the level of the hippocampus, and subiculum in particular. Findings were seen in a large sample, with the latest segmentation technology, and field-standard methods for controlling for potential confounds. If replicated in other samples and with other methods, early reserve for women in memory and hippocampal integrity could suggest need for changes in how and when women are screened for early signs of AD and how their progress is measured in clinical trials.
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